By preventing aberrant TF production by AML blasts and inflammatory monocytes, inhibition of PDI and other thiol isomerases may thus be a promising therapeutic approach in the management of AML-associated coagulation disorders. The gene discussed is TF; the disease is acute myeloid leukemia.